Literature DB >> 12734356

Prevalent role of TCR alpha-chain in the selection of the preimmune repertoire specific for a human tumor-associated self-antigen.

Pierre-Yves Dietrich1, Frédérique-Anne Le Gal, Valérie Dutoit, Mikäel J Pittet, Lydie Trautman, Alfred Zippelius, Isabelle Cognet, Valérie Widmer, Paul R Walker, Olivier Michielin, Philippe Guillaume, Thierry Connerotte, Francine Jotereau, Pierre G Coulie, Pedro Romero, Jean-Charles Cerottini, Marc Bonneville, Danila Valmori.   

Abstract

The specificity of recognition of pMHC complexes by T lymphocytes is determined by the V regions of the TCR alpha- and beta-chains. Recent experimental evidence has suggested that Ag-specific TCR repertoires may exhibit a more V alpha- than V beta-restricted usage. Whether V alpha usage is narrowed during immune responses to Ag or if, on the contrary, restricted V alpha usage is already defined at the early stages of TCR repertoire selection, however, has remained unexplored. Here, we analyzed V and CDR3 TCR regions of single circulating naive T cells specifically detected ex vivo and isolated with HLA-A2/melan-A peptide multimers. Similarly to what was previously observed for melan-A-specific Ag-experienced T cells, we found a relatively wide V beta usage, but a preferential V alpha 2.1 usage. Restricted V alpha 2.1 usage was also found among single CD8(+) A2/melan-A multimer(+) thymocytes, indicating that V alpha-restricted selection takes place in the thymus. V alpha 2.1 usage, however, was independent from functional avidity of Ag recognition. Thus, interaction of the pMHC complex with selected V alpha-chains contributes to set the broad Ag specificity, as underlined by preferential binding of A2/melan-A multimers to V alpha 2.1-bearing TCRs, whereas functional outcomes result from the sum of these with other interactions between pMHC complex and TCR.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12734356     DOI: 10.4049/jimmunol.170.10.5103

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  32 in total

Review 1.  Determinants of public T cell responses.

Authors:  Hanjie Li; Congting Ye; Guoli Ji; Jiahuai Han
Journal:  Cell Res       Date:  2012-01-03       Impact factor: 25.617

2.  Identification and engineering of human variable regions that allow expression of stable single-chain T cell receptors.

Authors:  David H Aggen; Adam S Chervin; Francis K Insaidoo; Kurt H Piepenbrink; Brian M Baker; David M Kranz
Journal:  Protein Eng Des Sel       Date:  2010-12-14       Impact factor: 1.650

3.  In vivo 6-thioguanine-resistant T cells from melanoma patients have public TCR and share TCR beta amino acid sequences with melanoma-reactive T cells.

Authors:  Cindy L Zuleger; Michael D Macklin; Bret L Bostwick; Qinglin Pei; Michael A Newton; Mark R Albertini
Journal:  J Immunol Methods       Date:  2010-12-21       Impact factor: 2.303

4.  Protein-protein interaction investigated by steered molecular dynamics: the TCR-pMHC complex.

Authors:  Michel A Cuendet; Olivier Michielin
Journal:  Biophys J       Date:  2008-07-11       Impact factor: 4.033

5.  Germ line-governed recognition of a cancer epitope by an immunodominant human T-cell receptor.

Authors:  David K Cole; Fang Yuan; Pierre J Rizkallah; John J Miles; Emma Gostick; David A Price; George F Gao; Bent K Jakobsen; Andrew K Sewell
Journal:  J Biol Chem       Date:  2009-07-15       Impact factor: 5.157

6.  Distinct sets of alphabeta TCRs confer similar recognition of tumor antigen NY-ESO-1157-165 by interacting with its central Met/Trp residues.

Authors:  Laurent Derré; Marc Bruyninx; Petra Baumgaertner; Mathias Ferber; Daphné Schmid; Antoine Leimgruber; Vincent Zoete; Pedro Romero; Olivier Michielin; Daniel E Speiser; Nathalie Rufer
Journal:  Proc Natl Acad Sci U S A       Date:  2008-09-22       Impact factor: 11.205

7.  Optimization of T-cell Reactivity by Exploiting TCR Chain Centricity for the Purpose of Safe and Effective Antitumor TCR Gene Therapy.

Authors:  Toshiki Ochi; Munehide Nakatsugawa; Kenji Chamoto; Shinya Tanaka; Yuki Yamashita; Tingxi Guo; Hiroshi Fujiwara; Masaki Yasukawa; Marcus O Butler; Naoto Hirano
Journal:  Cancer Immunol Res       Date:  2015-05-05       Impact factor: 11.151

8.  CD28neg. T lymphocytes of a melanoma patient harbor tumor immunity and a high frequency of germline-encoded and public TCRs.

Authors:  Hisayoshi Hashimoto; Marco Sterk; Karin Schilbach
Journal:  Immunol Res       Date:  2018-02       Impact factor: 2.829

9.  Topoisomerase inhibitors modulate expression of melanocytic antigens and enhance T cell recognition of tumor cells.

Authors:  Timothy J Haggerty; Ian S Dunn; Lenora B Rose; Estelle E Newton; Sunil Martin; James L Riley; James T Kurnick
Journal:  Cancer Immunol Immunother       Date:  2010-10-30       Impact factor: 6.968

Review 10.  Profile of a serial killer: cellular and molecular approaches to study individual cytotoxic T-cells following therapeutic vaccination.

Authors:  Emanuela M Iancu; Petra Baumgaertner; Sébastien Wieckowski; Daniel E Speiser; Nathalie Rufer
Journal:  J Biomed Biotechnol       Date:  2010-11-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.